NCT01540760

A Study of MCAF5352A in Healthy Volunteers

A Phase Ib, Single-Center, Randomized, Placebo-Controlled, Double-Blind Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Genentech, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This single-center, randomized, placebo-controlled, double-blind, multiple ascending dose study will evaluate the safety, pharmacokinetics and immunogenicity of MCAF5352A in healthy volunteers. Subjects will be randomized to receive either MCAF5352A or placebo on Days 1, 15 and 29.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	MCAF5352A	Multiple ascending doses
DRUG	Placebo	Matching MCAF5352A, multiple doses

Timeline

• Start date: 2012-03-01
• Primary completion: 2012-09-01
• Completion: 2012-09-01
• First posted: 2012-02-29
• Last updated: 2016-11-02

Locations

1 site across 1 country: Canada